Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) is thrilled to announce that its senior management team will be taking part in a series of upcoming investor conferences. Don’t miss this exciting chance to hear from the team and gain insights into the Company’s progress and future plans!
About Innate Pharma
Innate Pharma S.A. is a pioneering biotechnology company on a mission to revolutionize cancer treatments with their innovative immunotherapy approach. Through their proprietary ANKET® platform, they are leveraging the power of the body’s innate immune system to develop antibody-based therapies that can give hope to cancer patients around the world.
Innate is at the forefront of the fight against cancer, with a portfolio of innovative treatments that are revolutionizing the field. Its lead proprietary program, lacutamab, is being developed for advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas.
In addition, Innate has partnered with AstraZeneca to develop monalizumab for non-small cell lung cancer. Finally, its ANKET® multi-specific NK cell engagers offer potential for tackling multiple tumor types. With these groundbreaking treatments, Innate is paving the way for a brighter future in cancer care.
Innate Pharma is on a mission to revolutionize the biopharmaceutical industry by partnering with renowned research institutions, Sanofi, and AstraZeneca to drive innovation, research and development initiatives that bring forth treatments and cures to benefit patients.
Headquartered in the picturesque port city of Marseille, France, with a US office in Rockville, MD, Innate Pharma is a publicly-traded company listed on both the Euronext Paris and Nasdaq stock exchanges. With a mission to develop innovative therapeutic antibodies to improve the lives of patients with cancer, Innate Pharma is leading the charge in the global biopharmaceutical industry.